Based on the Pharming Group NV stock forecast from 0 analysts, the average analyst target price for Pharming Group NV is not available over the next 12 months. Pharming Group NV’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pharming Group NV is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Pharming Group NV’s stock price was EUR 0.77. Pharming Group NV’s stock price has changed by -10.92% over the past week, -6.20% over the past month and -25.94% over the last year.
No recent analyst target price found for Pharming Group NV
No recent average analyst rating found for Pharming Group NV
Company Overview Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Read Less
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibit...Read More
Frequently Asked Questions About Pharming Group NV (PHGN:F) Stock
Stock Target Advisor's fundamental analysis for Pharming Group NV's stock is Slightly Bearish.
Unfortunately we do not have enough data on PHGN:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PHGN:F's stock to indicate what its average analyst target is.
PHGN:F stock's Price/Earning ratio is 58.20.
Our analysis grades PHGN:F stock's Price / Earning ratio at F. This means that PHGN:F stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the F exchange.
Based on this PHGN:F may be a overvalued for its sector.
The last closing price of PHGN:F's stock was EUR 0.77.
The most recent market capitalization for PHGN:F is EUR 0.52B.
Unfortunately we do not have enough analyst data on PHGN:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pharming Group NV's stock.
As per our most recent records Pharming Group NV has 382 Employees.
Pharming Group NV's registered address is Darwinweg 24, Leiden, Netherlands, 2333 CR.
You can get more information about it from Pharming Group NV's website at https://www.pharming.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Pharming Group NV (PHGN:F) Stock
Stock Target Advisor's fundamental analysis for Pharming Group NV's stock is Slightly Bearish.
Unfortunately we do not have enough data on PHGN:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PHGN:F's stock to indicate what its average analyst target is.
PHGN:F stock's Price/Earning ratio is 58.20.
Our analysis grades PHGN:F stock's Price / Earning ratio at F. This means that PHGN:F stock's Price/Earning ratio is above 79% of the stocks in the Biotechnology sector in the F exchange.
Based on this PHGN:F may be a overvalued for its sector.
The last closing price of PHGN:F's stock was EUR 0.77.
The most recent market capitalization for PHGN:F is EUR 0.52B.
Unfortunately we do not have enough analyst data on PHGN:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Pharming Group NV's stock.
As per our most recent records Pharming Group NV has 382 Employees.
Pharming Group NV's registered address is Darwinweg 24, Leiden, Netherlands, 2333 CR.
You can get more information about it from Pharming Group NV's website at https://www.pharming.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PHGN:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
